Objectives: To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization.
Design: Randomized control trial.
Setting: Acute emergency medical admission unit in a regional teaching hospital in Hong Kong.
Patients: One hundred fifty adult patients with acute AF and rapid VR (>120 bpm).
Interventions: Patients were randomly assigned in 1:1:1 ratio to receive intravenous diltiazem, digoxin, or amiodarone for VR control.
Measurements And Main Results: The primary end point was sustained VR control (<90 bpm) within 24 hours; the secondary end points included AF symptom improvement and length of hospitalization. At 24 hours, VR control was achieved in 119 of 150 patients (79%). The time to VR control was significantly shorter among patients in the diltiazem group (log-rank test, p < 0.0001) with the percentage of patients who achieved VR control being higher in the diltiazem group (90%) than the digoxin group (74%) and the amiodarone group (74%). The median time to VR control was significantly shorter in the diltiazem group (3 hours, 1-21 hours) compared with the digoxin (6 hours, 3-15 hours, p < 0.001) and amiodarone groups (7 hours, 1-18 hours, p = 0.003). Furthermore, patients in the diltiazem group persistently had the lowest mean VR after the first hour of drug administration compared with the other two groups (p < 0.05). The diltiazem group had the largest reduction in AF symptom frequency score and severity score (p < 0.0001). In addition, length of hospital stay was significantly shorter in the diltiazem group (3.9 +/- 1.6 days) compared with digoxin (4.7 +/- 2.1 days, p = 0.023) and amiodarone groups (4.7 +/- 2.2 days, p = 0.038).
Conclusions: As compared with digoxin and amiodarone, intravenous diltiazem was safe and effective in achieving VR control to improve symptoms and to reduce hospital stay in patients with acute AF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCM.0b013e3181a02f56 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metoprolol vs diltiazem for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis of adverse events.
Am J Emerg Med
December 2024
Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Departments of Pharmacy and Emergency Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address:
Background: Intravenous (IV) diltiazem and metoprolol are commonly used to achieve rate control for atrial fibrillation with RVR (Afib with RVR), and are both recommended as first-line by current guidelines. While prior studies investigated the efficacy of these medications, there is little evidence available regarding the risk of adverse events (AEs) with their use.
Methods: We identified randomized controlled trials (RCT) and observational studies reporting rates of AEs following administration of IV diltiazem and metoprolol for Afib with RVR by searching PubMed, SCOPUS, EMBASE, and Cochrane Library.
Angiotensin-Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) Use are Associated With Increased Readmission After Ileostomy Creation.
Am Surg
December 2024
Kaiser Permanente Northwest, Portland, OR, USA.
Background: High output is a common cause for readmission after new ileostomy creation. The loss of sodium leads to compensatory activation of the renin-angiotensin-aldosterone system (RAAS). Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are first-line therapy for hypertension in the United States.
View Article and Find Full Text PDFReducing diltiazem-related hypotension in atrial fibrillation: Role of pretreatment intravenous calcium.
Am J Emerg Med
November 2024
University of Health Sciences, Haseki Training and Research Hospital, Department of Emergency Medicine, Istanbul, Türkiye.
Article Synopsis
- This study investigated if intravenous calcium pretreatment can help prevent hypotension caused by diltiazem in adults with atrial fibrillation or flutter and fast heart rates.
- A total of 217 patients participated, being assigned to either a placebo group or groups receiving different doses of IV calcium before treatment with diltiazem.
- Results showed that calcium pretreatment was effective in preventing hypotension without reducing the effectiveness of diltiazem in controlling heart rates, and no significant side effects were noted between groups.
Comparative safety and efficacy of a hybrid intravenous and oral diltiazem protocol for acute rate control in the emergency department.
Am J Emerg Med
November 2024
School of medicine, University of Galway, Ireland.
Efficacy and Safety of Intravenous Diltiazem Versus Metoprolol in the Management of Atrial Fibrillation with Rapid Ventricular Response in the Emergency Department: A Comprehensive Umbrella Review of Systematic Reviews and Meta-analyses.
J Innov Card Rhythm Manag
September 2024
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Article Synopsis
- Atrial fibrillation (AF) is a common heart rhythm disorder in the U.S. that affects millions, and it can lead to serious complications like rapid ventricular response (RVR).
- An umbrella review of existing systematic reviews found IV diltiazem was more effective than IV metoprolol for controlling heart rate and reducing ventricular rates in patients experiencing AF with RVR.
- However, the use of IV diltiazem was also associated with a higher risk of hypotension, indicating the need for further research to evaluate the balance between efficacy and safety for these treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!